The Australian registry of anti-epileptic drugs in pregnancy: Experience after 30 months

Journal of Clinical Neuroscience

Volumn 10, Issue 5, 2003, Pages 543-549

  Vajda, Frank J ^a,b   O'Brien, Terence J ^b   Hitchcock, Alison ^a   Graham, Janet ^a   Lander, Cecilie ^c  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; FOLIC ACID; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANENCEPHALUS; ARNOLD CHIARI MALFORMATION; ARTICLE; BIRTH DEFECT; CLEFT PALATE; CLINODACTYLY; CLUBFOOT; COMPARATIVE STUDY; CONCEPTION; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONTROLLED STUDY; CRANIOFACIAL MALFORMATION; DOSE RESPONSE; DRUG SAFETY; DRUG SCREENING; ECHOGRAPHY; EPILEPSY; EXPERIMENTAL MODEL; FACE DYSMORPHIA; FEMALE; FINGER MALFORMATION; FIRST TRIMESTER PREGNANCY; FOLLOW UP; HIGH RISK PREGNANCY; HOLOPROSENCEPHALY; HUMAN; HYDROCEPHALUS; HYPOSPADIAS; INCIDENCE; INDUCED ABORTION; KIDNEY DUPLICATION; MAJOR CLINICAL STUDY; MEDICAL RECORD; NEURAL TUBE DEFECT; OUTCOMES RESEARCH; PLAGIOCEPHALY; POLYDACTYLY; PREGNANCY COMPLICATION; PREMATURE LABOR; PRIORITY JOURNAL; SEIZURE; SKELETON MALFORMATION; SPINA BIFIDA; SPONTANEOUS ABORTION; STILLBIRTH; TREATMENT OUTCOME; URINARY TRACT DISEASE; VITAMIN SUPPLEMENTATION;

EID: 0141670265     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-5868(03)00158-9     Document Type: Article

References (39)

1. Janz D, Fuchs U. Are anti-epileptic drugs harmful when given during pregnancy? Dtsch Med Monatsschr 1964; 9: 20.
2. Meadow SR. Anticonvulsant drugs and congenital anomalies. Lancet 1968; 2: 1269.
3. Bjerkdal T, Bahna SL. The course and outcome of pregnancy in women with epilepsy. Acta Obstet Gynecol Scand 1973; 52: 245-248.
4. Nakane Y, Oltuma T, Takahashi R et al. Multi-institutional study on the teratogenicity and fetal toxicity of anticonvulsants: a report of a collaberative study group in Japan. Epilepsia 1980; 21: 663-680.
5. Majewaski F, Steger M, Richter B, Gill J, Rabe F. The teratogenicity of hydantoins and barbiturates in humans, with considerations on the etiology of malformations and cerebral disturbances in children of epileptic parents. Biol Res Pregnancy 1980; 2: 37.
6. Fedrick J. Epilepsy and pregnancy: a report from the Oxford record linkage study. Br Med J 1983; 2: 442-448.
7. Speidal BD, Meadow SR, Maternal epilepsy and abnormalities of the fetus and the newborn. Lancet 1972; 2: 839-843.
8. Lindhout D, Meinardi H, Meijer WA, Nau H. Antiepileptic drugs and teratogenisis in two consecutive cohorts: changes in prescription policy paralleled by changes in patterns of malformations. Neurology 1992; 42(Suppl 5): 94-110.
9. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and "reproductive outcome" epidemiologic and experimental findings spanning three decades; 2: Human studies. Reprod Toxicol 1991; 5: 301-335.
10. Sawhney H, Vasishta K, Suri V, Khunnu B, Goel P, Sawhney IM. Pregnancy with epilepsy - a retrospective analysis. Int J Gynaecol Obstet 1996; 54: 17-22.
11. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Childhood 1996; 75: 517-520.
12. Jick SS, Terris BZ. Anticonvulsants and congenital malformations. Pharmacotherapy 1997; 17: 561-564.
13. Sabers A, Rogvi-Hansen B, Dam M et al. Pregnancy and epilepsy: a retrospective study of 151 pregnancies. Acta Neurol Scand 1998; 97: 164-170.
14. Riley M, Halliday J. Birth defects in Victoria 1983-1998, Perinatal Data Collection Unit, Victorian Government Department of Human Services, Victorian Government Department of Human Services, Melbourne 2000.
15. Kalter H, Warkany J. Congenital malformations. N Engl J Med 1983; 308: 491-497.
16. Dolk H, McElhatton P. Assessing epidemiological evidence for the teratogenic effects of anticonvulsant medications. J Med Genet 2002; 39: 243-244.
17. Stumpf DA, Frost M. Seizures, anticonvulsants, and pregnancy. Am H Dis Child 1978; 132: 746-748.
18. Higgins TA, Commerford JB. Epilepsy and pregnancy. J Irish Med Assoc 1974; 67: 317-320.
19. Teramo K, Hiilesmaa VK. Pregnancy and fetal complications in epileptic pregnancies: review of the literature. In: Janz D, Bossi L, Dam M, et al. (eds) Epilepsy, Pregnancy and the Child. Raven Press, New York 1982; 53-59.
20. Wallace H, Shorvon S, Tallis R. Age specific incidence and prevalence rates of treated epilepsy in an unselected population of 2 052 922 and age-specific fertility rates of women with epilepsy. Lancet 1998; 352: 1970-1973.
21. Holmes LB, Harvey EA, Coull BA et al. The teratogenicity of anticonvulsant drugs. NEJM 2001; 344: 1132-1138.
22. O'Brien TJ, Vajda FJ. Contemporary management of epilepsy in pregnancy. Aust N Z J Obstet Gynaecol 2000; 40: 413-415.
23. Dean JCS, Hailey H, Moore SJ, Lloyd DJ, Turnpenny PD, Little J. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Gent 2002; 39: 251-259.
24. Kaneko S, Otani K, Fukushima Y et al. Malformations in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology 1992; 42(Suppl 5): 68-74.
25. Wide K, Winbladh B, Tomson T, Källén B. Body dimensions of infants exposed to antiepileptic drugs in utero: observations spanning 25 years. Epilepsia 2000; 41: 854-861.
26. Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet 1998; 68: 18-24.
27. Choulika S, Harvey E, Holmes LB. Effect of antiepileptic drugs (AED) on fetal growth: assessment at birth. Teratology 1999; 59: 388.
28. Biale Y, Lewenthal H. Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. Eur J Obstet Gynecol Reprod Biol 1984; 18: 211-216.
29. Craig J, Morrison P, Morrow J, Patterson V. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 1999; 8: 253-254.
30. Smithells RW, Nevin NC, Seller MJ et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1983; 1: 1027-1031.
31. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube detects. BMJ 1981; 282: 1509-1511.
32. Bower C, Stanley FJ. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. Med J Aust 1981; 150: 613-619.
33. Milunsky A, Jick H, Jick SS et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989; 262: 2847-2852.
34. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131-137.
35. Kadir RA, Sabin C, Whitlow B, Brockbank E, Economides D. Neural tube defects and periconceptional folic acid in England and Wales: retrospective study. BMJ 1999; 319: 92-93.
36. Berry RJ, Li Z, Erickson JD et al. Prevention of neural-tube defects with folic acid in China. NEJM 1999; 341: 1485-1490.
37. Phelan MC, Pellock JM, Nance WE. Discordant expression of fetal hydantoin syndrome in heteropaternal dizygotic twins. N Engl J Med 1982; 307: 99-101.
38. Van Dyke DC, Hodge SE, Helde F, Hill LR. Family studies in fetal hydantoin syndrome. J Pediatr 1988; 113: 301-306.
39. Lundberg YW, Greer KA, Zhao J et al. Mapping of a chromosomal locus for valproic acid-induced neural tube defects. Am J Hum Genet 2000; 67(Suppl 2): 20.